Comparative Pharmacology
Head-to-head clinical analysis: CENTANY versus SILVADENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTANY versus SILVADENE.
CENTANY vs SILVADENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to microbial DNA and proteins, inhibiting cell wall synthesis and cell division. The sulfadiazine component provides additional bacteriostatic action by competing with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase in folic acid synthesis.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
Apply a thin layer (approximately 1/16 inch) of 1% cream to the affected area once or twice daily. Use a sterile gloved hand. Reapply as needed to maintain coverage.
None Documented
None Documented
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
The terminal elimination half-life of sulfadiazine is approximately 10-12 hours in patients with normal renal function. Silver has a very long biological half-life (weeks to months) due to tissue deposition.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Silver sulfadiazine applied topically results in minimal systemic absorption. The sulfadiazine component is primarily excreted renally (approximately 70% as unchanged drug and metabolites), with biliary/fecal excretion accounting for a small fraction (<10%). Silver is largely retained in tissues, not excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic